Tecentriq Approved for Metastatic Non-Small Cell Lung Cancer

October 18, 2016

The US Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab (Tecentriq, Genentech) for use in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed during or after treatment with a platinum-based chemotherapy or appropriate targeted therapy, the manufacturer announced today.

Atezolizumab, a programmed cell death ligand-1 (PD-L1) inhibitor, was first approved in May for treatment of urothelial carcinoma. Researchers are currently testing the drug in patients with metastatic renal cell carcinoma or advanced melanoma.

The FDA determined that atezolizumab was safe and effective for treating NSCLC based on the phase III OAK and phase II POPLAR studies. In the OAK study, patients receiving atezolizumab lived a median 4.2 months longer than those treated with docetaxel chemotherapy.

Adverse events reported for atezolizumab include pneumonitis, hepatitis, colitis, hormone gland problems, neuropathy, eye inflammation, severe infections, and severe infusion reactions.

More information on the FDA decision is available on the manufacturer's website.

Follow Robert Lowes on Twitter @LowesRobert


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.